3DMedcare

3DMedcare, also known as 3D Medicines, is a biotechnology company based in Shanghai, China, founded in 2010. The company specializes in oncology precision medical testing, diagnostics, and the development of immuno-oncology drugs. It integrates various fields, including engineering and life sciences, to enhance research and development, manufacturing, and data processing in precision diagnosis. 3DMedcare is a leader in automated precision diagnostics, offering services that range from early disease diagnosis to dynamic monitoring. The company has developed significant platforms for oncology testing, including the world's largest marker development platform for liver cancer. Its drug development pipeline features innovative immuno-oncology drugs, such as Envafolimab, the first subcutaneous PD-L1 antibody in clinical development across multiple countries. With partnerships involving over 800 hospitals in China, 3DMedcare aims to provide comprehensive precision medicine solutions to improve cancer management.